Jazz Pharmaceuticals (NASDAQ:JAZZ) Lowered to “Neutral” Rating by Cantor Fitzgerald

Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from an overweight rating to a neutral rating in a research report report published on Wednesday morning, Marketbeat reports. Cantor Fitzgerald currently has $150.00 price target on the specialty pharmaceutical company’s stock, up from their previous price target of $140.00.

A number of other research analysts have also recently issued reports on the company. Needham & Company LLC lifted their target price on Jazz Pharmaceuticals from $205.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $130.00 to $170.00 in a report on Thursday, February 13th. TD Cowen reduced their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $182.47.

Jazz Pharmaceuticals Stock Up 3.2 %

JAZZ opened at $144.17 on Wednesday. The company has a market capitalization of $8.72 billion, a P/E ratio of 20.31, a P/E/G ratio of 1.04 and a beta of 0.56. The stock has a fifty day moving average of $125.42 and a 200-day moving average of $118.44. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 5,053 shares of company stock valued at $617,442 over the last ninety days. 4.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. grew its holdings in Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company’s stock worth $115,681,000 after buying an additional 507,234 shares in the last quarter. Darwin Global Management Ltd. bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth $59,668,000. Dimensional Fund Advisors LP grew its holdings in Jazz Pharmaceuticals by 18.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock worth $250,619,000 after buying an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock worth $225,076,000 after buying an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp grew its stake in Jazz Pharmaceuticals by 140.0% in the 4th quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company’s stock valued at $62,659,000 after purchasing an additional 296,800 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.